Transforming Existing Businesses and Enhancing Corporate Value through the 2017 Medipal Medium-Term Vision
First written in FY2016. 17 of 27 entries say "Restated". Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026RestatedAnnual report
「Based on its human resources and financial strategies, the Group is pursuing 5 growth strategies through shifts in its business portfolio and collaboration with partners: “expansion overseas”; “expansion in prevention, pre-disease care and the agro-foods sector”; “strengthening the business platform through digital technologies”; “building sustainable distribution”; and “co-creating value in regional healthcare.” The Group aims to create new social and customer value and achieve sustainable growth.」
The Group continues to pursue the 2027 Medipal Medium-Term Vision and its 5 growth strategies. The targets of ROE of 9%, ordinary income of ¥100 billion, cumulative growth investment of ¥100 billion and a total shareholder return payout ratio of 40% are also being maintained. - 2026-05-25RestatedGeneral Meetings of Shareholders
「Under the “2027 メディパル Medium-Term Vision: Change the 卸 Forever — Continuous Transformation,” the メディパル Group continues to make proactive investments and take on challenges with the aim of creating new social and customer value and achieving sustainable growth for the Group.」
The Company reiterated its policy of creating social and customer value and pursuing sustainable growth under the 2027 メディパル Medium-Term Vision. - FY2024RestatedAnnual report
「<Key consolidated management targets and plan> ROE 9% (fiscal year ending March 2027) Ordinary income ¥100 billion (fiscal year ending March 2027) Growth investment ¥100 billion in cumulative investment from the fiscal year ending March 2023 through the fiscal year ending March 2027」
The Group continues to state the 2027 Medipal Medium-Term Vision’s targets of ROE of 9%, ordinary income of ¥100 billion and cumulative growth investment of ¥100 billion. - FY2023AdvancedAnnual report
「<Key consolidated management targets and plan> ROE 9% (fiscal year ending March 2027) Ordinary income ¥100 billion (fiscal year ending March 2027) Growth investment ¥100 billion in cumulative investment from the fiscal year ending March 2023 through the fiscal year ending March 2027」
For the 2027 Medipal Medium-Term Vision, the Group presented new specific targets of ROE of 9%, ordinary income of ¥100 billion and cumulative growth investment of ¥100 billion from the fiscal year ending March 2023 through the fiscal year ending March 2027. It also specified 5 growth strategies: overseas expansion; prevention, pre-disease care and the agro-foods sector; digital; sustainable distribution; and regional healthcare. - FY2023-Q3RestatedAnnual report
「In the business fields of “medical care and health, and beauty,” the Group aims to create a new form of wholesaling that contributes to society. In line with the “2027 Medipal Medium-Term Vision: Change the 卸 Forever — Relentless Transformation,” we will develop businesses that leverage the Group’s strengths without being constrained by conventional frameworks, thereby contributing to the realization of a society in which everyone can enjoy physical and mental health.」
In line with the 2027 Medipal Medium-Term Vision, the Group continues to develop businesses unconstrained by conventional frameworks and contribute to society through physical and mental health. - FY2023-Q2ReframedAnnual report
「The Company newly formulated and announced on 31 October 2022 the “2027 Medipal Medium-Term Vision: Change the 卸 Forever — Relentless Transformation,” whose final year is the fiscal year ending March 2027. In the business fields of “medical care and health, and beauty,” we will develop businesses that leverage the Group’s strengths without being constrained by conventional frameworks, thereby contributing to the realization of a society in which everyone can enjoy physical and mental health.」
The plan was revised from the previous plan centred on the fiscal year ending March 2023 to the “2027 Medipal Medium-Term Vision,” whose final year is the fiscal year ending March 2027. It sets out business development unconstrained by conventional frameworks and contribution to society through physical and mental health. - FY2022ReframedAnnual report
「<Key consolidated management targets and plan> Revenue ¥3.333 trillion (fiscal year ending March 2023) Operating income ¥46.5 billion (fiscal year ending March 2023) Ordinary income ¥63.3 billion (fiscal year ending March 2023)」
Following 3 years of initiatives through the fiscal year ending March 2022, the Group presented new consolidated management targets and a plan for the fiscal year ending March 2023: revenue of ¥3.333 trillion, operating income of ¥46.5 billion and ordinary income of ¥63.3 billion. - FY2022-Q3RestatedAnnual report
「The Group is pursuing initiatives in line with a vision that looks ahead to changes in the social environment, with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” While further innovating existing businesses, new businesses have advanced from “creation” to “expansion.” At the same time, we aim to further expand our earnings base and achieve sustainable growth by building new frameworks that contribute to society and customers through partnerships with companies in various fields. As a company responsible for distribution, we will also contribute to achieving a sustainable society, including by reducing our environmental impact.」
The Group continues its direction of pursuing a vision that looks ahead to changes in the social environment, innovating existing businesses, expanding new businesses, partnering with companies, expanding the earnings base and reducing environmental impact. - FY2022-Q1RestatedAnnual report
「The Group is pursuing initiatives under the “2022 Medipal Medium-Term Vision: Change the 卸 Future — Transformation for the Future,” a vision that looks ahead to changes in the social environment, with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” While further innovating existing businesses, new businesses have advanced from “creation” to “expansion.” At the same time, we aim to further expand our earnings base and achieve sustainable growth by building new frameworks that contribute to society and customers through partnerships with companies in various fields. As a company responsible for distribution, we will also contribute to achieving a sustainable society, including by reducing our environmental impact.」
The Group explicitly states the name of the 2022 Medipal Medium-Term Vision and continues its previous direction of innovating existing businesses, expanding new businesses, partnering with companies, expanding the earnings base and reducing environmental impact. - FY2021RestatedAnnual report
「<Key consolidated management targets (targets or policies under the medium-term management plan)> Ordinary income ¥72 billion (fiscal year ending March 2022) Profit from new businesses* ¥10 billion (fiscal year ending March 2022) Payout ratio Stable dividends, with 30% as a guideline Growth investment Approximately ¥100 billion over 3 years」
The Group continues the 2022 Medipal Medium-Term Vision’s targets and policies of ordinary income of ¥72 billion, profit from new businesses of ¥10 billion, a payout ratio of 30% and growth investment of approximately ¥100 billion over 3 years. - FY2021-Q2RestatedAnnual report
「The Group aims to create a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty,” and is pursuing initiatives in line with a vision that looks ahead to changes in the social environment. While further innovating existing businesses, new businesses have advanced from “creation” to “expansion.” At the same time, we are building new frameworks that contribute to society and customers through partnerships with companies in various fields, with the aim of further expanding our earnings base and achieving sustainable growth.」
The Group continues its policy of pursuing a vision that looks ahead to changes in the social environment, innovating existing businesses, expanding new businesses and expanding the earnings base through partnerships. - FY2021-Q1AdvancedAnnual report
「The Group aims to create a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty,” and is pursuing initiatives in line with a vision that looks ahead to changes in the social environment. While further innovating existing businesses, new businesses have advanced from “creation” to “expansion.” At the same time, we are building new frameworks that contribute to society and customers through partnerships with companies in various fields, with the aim of further expanding our earnings base and achieving sustainable growth.」
It states that new businesses have advanced from the previous stage of “creation” to “expansion,” and that the Group continues to build new frameworks through partnerships with companies. - FY2020AdvancedAnnual report
「<Key consolidated management targets (targets or policies for the fiscal year ending March 2022)> Ordinary income ¥72 billion Profit from new businesses ¥10 billion Payout ratio Stable dividends, with 30% as a guideline Growth investment Approximately ¥100 billion over 3 years」
For the new medium-term vision ending in the fiscal year ending March 2022, the Group specified targets and policies of ordinary income of ¥72 billion, profit from new businesses of ¥10 billion, a payout ratio of 30% and growth investment of approximately ¥100 billion over 3 years. - FY2020-Q3RestatedAnnual report
「The Group aims to create a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” It newly formulated and announced a vision on 15 May 2019 that looks ahead to changes in the social environment. While further innovating existing businesses, we will advance new businesses from “creation” to “expansion.” At the same time, we will build new frameworks that contribute to society and customers through partnerships with companies in various fields, thereby further expanding our earnings base and achieving sustainable growth.」
The Group continues its policy of pursuing the new vision announced in May 2019, innovating existing businesses, moving new businesses from creation to expansion, and expanding the earnings base through partnerships with companies. - FY2020-Q2RestatedAnnual report
「The Group aims to create a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” It newly formulated and announced a vision on 15 May 2019 that looks ahead to changes in the social environment. While further innovating existing businesses, we will advance new businesses from “creation” to “expansion.” At the same time, we will build new frameworks that contribute to society and customers through partnerships with companies in various fields, thereby further expanding our earnings base and achieving sustainable growth.」
The Group continues its policy of pursuing the new vision announced in May 2019, innovating existing businesses, moving new businesses from “creation” to “expansion,” and expanding the earnings base through partnerships with companies. - FY2020-Q1ReframedAnnual report
「The Group aims to create a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” It newly formulated and announced a vision on 15 May 2019 that looks ahead to changes in the social environment. While further innovating existing businesses, we will advance new businesses from “creation” to “expansion.” At the same time, we will build new frameworks that contribute to society and customers through partnerships with companies in various fields, thereby further expanding our earnings base and achieving sustainable growth.」
The Group moved from the 2019 Medipal Medium-Term Vision to a new vision reflecting changes in the social environment. New businesses are being advanced from the creation stage to the expansion stage, with an emphasis on partnerships with companies, innovation in existing businesses and expansion of the earnings base. A subsequent event also indicates that this is a 3-year medium-term vision covering the fiscal years ending March 2020 through March 2022. - FY2019-Q3RestatedAnnual report
「The Group is pursuing initiatives under the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, promoting new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The Group continues the 2019 Medipal Medium-Term Vision and its efforts to achieve sustainable growth through improving the efficiency of existing businesses, promoting new businesses, developing growth areas and expanding the earnings base. - FY2019-Q2RestatedAnnual report
「The Group is pursuing initiatives under the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, promoting new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The Group continues the 2019 Medipal Medium-Term Vision and its policy of achieving sustainable growth through improving the efficiency of existing businesses, promoting new businesses, developing growth areas and expanding the earnings base. - FY2019-Q1RestatedAnnual report
「The Group is pursuing initiatives under the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, expanding new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The Group continues to pursue the 2019 Medipal Medium-Term Vision and its policies of improving the efficiency of existing businesses, expanding new businesses, developing growth areas and expanding the earnings base. - FY2018AdvancedAnnual report
「As the target state for the fiscal year ending March 2019, we formulated the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation” and are pursuing initiatives in line with the vision.」
The targets for the fiscal year ending March 2019 were revenue of ¥3.26 trillion, operating income of ¥50 billion, including ¥5 billion from new businesses, ordinary income of ¥65 billion and total capital expenditures of ¥85 billion over 3 years. It states that progress over the 2 fiscal years through the current fiscal year was in line with expectations. - FY2018-Q3RestatedAnnual report
「The Group is pursuing initiatives under the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, promoting new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The Group continues its policy of improving the efficiency of existing businesses, promoting new businesses, developing growth areas and expanding the earnings base in line with the 2019 Medipal Medium-Term Vision. - FY2018-Q2RestatedAnnual report
「The Group is pursuing initiatives under the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, promoting new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The Group continues to pursue the 2019 Medipal Medium-Term Vision and its policies of improving the efficiency of existing businesses, promoting new businesses, developing growth areas and expanding the earnings base. - FY2017AdvancedAnnual report
「As the target state for the fiscal year ending March 2019, we formulated the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation” and are pursuing initiatives in line with the vision.」
For the medium-term vision ending in the fiscal year ending March 2019, the Group specified management targets of revenue of ¥3.26 trillion, operating income of ¥50 billion, including ¥5 billion from new businesses, and ordinary income of ¥65 billion, along with a plan for total capital expenditures of ¥85 billion over 3 years. - FY2017-Q3RestatedAnnual report
「Amid these economic conditions, the Group has formulated the 3-year “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” In addition to further improving the efficiency and expanding the functions of existing businesses and promoting the expansion of new businesses by leveraging infrastructure and human resources nationwide, we will develop businesses in growth areas by drawing on the functions and resources of Group companies, thereby expanding our earnings base and achieving sustainable growth for the Group.」
The Group is continuing the 2019 Medipal Medium-Term Vision as a 3-year plan and has reaffirmed its policy of improving the efficiency of existing businesses, expanding new businesses, developing growth areas and expanding the earnings base. - FY2017-Q2RestatedAnnual report
「The Group has formulated the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation,” covering the 3 fiscal years from the current consolidated fiscal year, with the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty.” In addition to further improving the efficiency and expanding the functions of existing businesses and promoting the expansion of new businesses by leveraging infrastructure and human resources nationwide, we will develop businesses in growth areas by drawing on the functions and resources of Group companies, thereby expanding our earnings base and achieving sustainable growth for the Group.」
The Group is continuing the 2019 Medipal Medium-Term Vision as a 3-year plan and has reaffirmed its policy of expanding the earnings base through greater efficiency in existing businesses, expansion of new businesses and development in growth areas. - FY2017-Q1ReframedAnnual report
「With the aim of creating a new form of wholesaling that contributes to society through the distribution of “medical care and health, and beauty,” we newly formulated the “2019 Medipal Medium-Term Vision: Change the 卸 next — Innovation and Creation.” We will expand our earnings base and achieve sustainable growth for the Group by further improving the efficiency and expanding the functions of existing businesses, expanding new businesses by leveraging infrastructure and human resources nationwide, and developing businesses in growth areas by drawing on the functions and resources of Group companies.」
The plan was revised from the previous 2017 Medium-Term Vision to the 2019 Medium-Term Vision. It sets out a new form of wholesaling, greater efficiency and expanded functions in existing businesses, expansion of new businesses, development in growth areas and expansion of the earnings base. - FY2016First statedAnnual report
「Under the “2017 Medipal Medium-Term Vision: Change the 卸 — Innovation and Creation,” we worked to innovate our existing businesses and diversify earnings by further strengthening the logistics and sales functions developed in each business and creating new businesses by leveraging our assets, human resources, funds and external resources. We also worked to achieve growth for the Group and further enhance corporate value. As a result, we achieved the operating income and ordinary income targets set under the vision one year ahead of schedule.」
The Group established a medium-term vision centred on 2017, with the integrated objectives of innovating existing businesses, creating new businesses, diversifying earnings and enhancing corporate value. It states that the operating income and ordinary income targets were achieved one year ahead of schedule.